^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cladribine

    i
    Other names: 2-CdA, 2-Chlorodeoxyadenosine, Chlorodeoxyadenosine, Intocel, Leustatine, N-l-Leucyl-doxorubicin
    Company:
    Generic mfg.
    Drug class:
    Purinergic receptor P1 agonist
    6d
    RG1121403: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1/2, N=62, Recruiting, University of Washington | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • mitoxantrone • cladribine • Starasid (cytarabine ocfosfate)
    8d
    042011: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis (2024-512676-36-00)
    P2/3, N=1124, Active, not recruiting, St. Anna Childrens Cancer Research Institute GmbH | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • methotrexate • cladribine • melphalan • fludarabine IV • mercaptopurine • vinblastine • prednisolone
    23d
    A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • SF3B1 mutation • Chr del(5q)
    |
    cytarabine • azacitidine • cladribine • melphalan • busulfan
    1m
    RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)
    P4, N=289, Recruiting, Medizinische Hochschule Hannover | N=128 --> 289
    Enrollment change • Minimal residual disease
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    1m
    Aggressive Systemic Mastocytosis Presenting as Diffuse Osteoblastic Bone Disease: A Diagnostic Pitfall Mimicking Metastatic Cancer. (PubMed, Eur J Case Rep Intern Med)
    Aggressive mastocytosis can rarely present with diffuse osteoblastic bone lesions mimicking metastatic disease.Elevated serum tryptase and histopathological confirmation are essential for diagnosis, even when KIT mutations are absent.Early recognition prevents unnecessary oncologic investigations and allows timely initiation of cytoreductive therapy.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD68 (CD68 Molecule)
    |
    KIT mutation
    |
    cladribine
    2ms
    RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)
    P4, N=128, Recruiting, Medizinische Hochschule Hannover | N=52 --> 128
    Enrollment change • Minimal residual disease
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    2ms
    A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, University of Rochester
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • cladribine
    3ms
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    3ms
    Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=65, Completed, First Affiliated Hospital of Zhejiang University | Recruiting --> Completed | N=30 --> 65 | Trial primary completion date: Aug 2025 --> Apr 2025
    Trial completion • Enrollment change • Trial primary completion date
    |
    cytarabine • cladribine • Synribo (omacetaxine mepesuccinate)
    3ms
    Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (clinicaltrials.gov)
    P3, N=167, Terminated, Delta-Fly Pharma, Inc. | N=450 --> 167 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; The data met the protocol-specified criteria for futility of the investigational treatment.
    Enrollment change • Trial completion date • Trial termination
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • decitabine • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • radgocitabine (DFP-10917)
    4ms
    NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)
    4ms
    SZBALL01: CAV Regimen for R/R Ph- B-ALL (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • cladribine